Search Results

The company behind the hormone-free contraceptive Phexxi®, Evofem Biosciences, Inc. announced financial results for the first quarter of 2024.

Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc.

Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,992,472, which covers composition and methods for contraception with a composition that encompasses Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel.

Women’s health innovator Evofem Biosciences, Inc. announced a new market partnership with Hello Alpha, a telemedicine company with a medical team specifically trained for a woman’s unique needs, to offer Phexxi®, the non-hormonal prescription vaginal gel FDA-approved to prevent pregnancy for those who choose to use an on-demand method of birth control.

Evofem Biosciences, Inc. (OTCQB: EVFM) today announced financial results for the third quarter and nine months ended September 30, 2023.

The company behind Phexxi® vaginal gel, women’s health innovator Evofem Biosciences, Inc., announced financial results for the fourth quarter and year ended December 31, 2023.

Evofem Biosciences, Inc. (OTCQB: EVFM) today announced strong preliminary, unaudited results for fiscal 2023, including record net sales of Phexxi® (lactic acid, citric acid, and potassium bitartrate), its hormone-free contraceptive gel, and the Company’s lowest total operating expenses since becoming a commercial stage company in 2020.

Commercial-stage women’s health innovator Evofem Biosciences, Inc. announced that it has successfully renegotiated the rebate for Phexxi®, its hormone-free, woman-controlled contraceptive, with Medi-Cal, the California state Medicaid program.